#VH20: Save the date! The 12th Annual Viral Hepatitis Conference will take place 16-18 August 2019 at the Sofitel B… https://t.co/pHUF5hYmqR
Amber D'Souza outlined the epidemiology of anal cancer pointing out the significantly elevated risks for HIV positive MSM. She found DARE acceptable to patients within a study of 327 men.
Dr Jason Ong posed the question "What should we be doing with our patients now?"
He gave compelling reasons to screen for anal cancer targetting the most at risk, that is HIV positive men > age 50 ideally with an annual digital rectal exam to try and detect anal cancer at an earlier stage than is currently achieved with reactive checks related to symptoms.
50% of anal cancers are visible externally ie just looking would make a huge difference and currently less than 10% of HIV positive MSM have annual anal exams.80-100% will be found with DARE.
It is a simple safe cost effective and acceptable practice and can lead to better outcomes.
The evidence for screening for precursor lesions seems less compelling.
HSIL is present in 30-50% of HIV positive gay men however only 1/400 progress to cancer in HIV positive men and 1/4000 progress to cancer in HIV negative men.
SPANC has greatly increased understanding of this process.?Highest risk to progression to anal cancer is seen in those with persisting HPV16.
It was also suggested by Jason and Dr David Templeton to consider HPV vaccination in this group as despite the lack of evidence for efficacy, it may work.
From positivelife NSW we learned that most PLHIV thought their risk for anal cancer was the same or lower than the general population.
84% of respondants in that survey and 64% HIV respondants had never talked to thier doctor about anal HPV/cancer- we should clearly be doing better than this.